ModifiedBlue Cross Blue Shield - MassachusettsPolicy 474

Vagus Nerve Stimulation (VNS) — Coverage Criteria

This policy governs coverage and prior authorization rules for implantable and non‑implantable vagus nerve stimulation devices for commercial members of Blue Cross Blue Shield of Massachusetts, including indications considered medically necessary and investigational.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyVagus Nerve Stimulation (VNS) — Coverage Criteria

Policy CodePolicy 474

Change TypeClarified investigational indicationsliterature update

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required when the VNS procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

Policy statements updated to include rheumatoid arthritis as an investigational indication for VNS.

Literature review updated through September 3, 2025 and references added.

4related policies

6CPT codes listed

multipleRCT evidence (epilepsy)

mixedevidence (TRD)

~74

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Vagus Nerve Stimulation

Covered Indications

Covered when ALL of the following are met

Medically necessary for seizures: Vagus nerve stimulation may be considered MEDICALLY NECESSARY as a treatment of medically refractory seizures.

Applies to Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity.

Investigational / Not Covered Indications

VNS is considered investigational for the following conditions or device types

Investigational conditions: Vagus nerve stimulation is considered INVESTIGATIONAL as a treatment of other conditions, including but not limited to heart failure, upper-limb impairment due to stroke, essential tremor, headaches, rheumatoid arthritis, fibromyalgia, tinnitus and traumatic brain injury.

Also considered investigational for psychiatric conditions including depression, treatment-resistant depression and obsessive compulsive disorder.

Transcutaneous VNS: Transcutaneous (nonimplantable) vagus nerve stimulation devices are considered INVESTIGATIONAL for all indications.

HCPCS code E0735 (non-invasive vagus nerve stimulator) is listed as investigational.

Covered when evidence sufficient

Indications with sufficient evidence or definitive conclusions:

Refractory partial-onset epilepsy: Implantable VNS has randomized controlled trials and multiple observational studies reporting significant reductions in seizure frequency; evidence is sufficient to determine an improvement in net health outcome.

Supported by RCTs and multiple observational studies.

Investigational / Insufficient Evidence

Indications considered investigational / insufficient evidence:

Treatment-resistant depression (implantable VNS): Multiple RCTs including sham-controlled trials show mixed results; short-term trials often negative on primary outcomes and longer-term or secondary measures show inconsistent benefit; evidence is insufficient to determine improvement in net health outcome.

Three RCTs and additional nonrandomized data have methodological limitations.

Chronic heart failure: Systematic review including 4 RCTs and case series found some improvements in functional class and biomarkers but limitations of uncontrolled longer-term data and inconsistent comparators limit conclusions; evidence insufficient.

Meta-analyses reported improvements but certainty inadequate for net health outcome determination.

Upper-limb impairment due to stroke: Three pilot RCTs with mixed results (one larger RCT positive, others negative or with safety concerns); pooled analysis suggests improvement in motor function but longer-term efficacy and safety data are lacking; evidence insufficient.

One trial reported serious adverse events related to surgery.

Other types of implantable vagus nerve stimulators that are placed in contact with the trunks of the vagus nerve at the gastroesophageal junction are not addressed in this evidence review.

Case series and uncontrolled data for miscellaneous indications (for example, essential tremor, fibromyalgia, tinnitus, and autism) are explicitly identified as insufficient to draw conclusions regarding efficacy. These uncontrolled reports do not provide adequate evidence to determine improvement in net health outcome, and such uses are considered investigational per this policy.

This policy includes a reference-only section citing external guidance documents. Providers and reviewers should consult National Institute for Health and Care Excellence (NICE) and Centers for Medicare & Medicaid Services (CMS) resources for additional context on coverage scope and recommendations (for example, NICE guidance on gammaCore and implanted VNS and CMS national coverage/CED documents). These external guidance sources may inform prior authorization and coverage determinations.

Transcutaneous or other nonimplantable vagus nerve stimulation devices are considered investigational for all indications in this policy. Use of tVNS/nVNS for non‑seizure indications (including cardiac, psychiatric, and many neurologic conditions) is not supported by definitive evidence and is categorized as investigational.

Randomized trials of noninvasive vagus nerve stimulation (nVNS) for prevention of chronic migraine have not consistently shown superiority to sham. The phase 3 PREMIUM trial (n=341) did not demonstrate statistically significant benefit on primary endpoints (eg, ≥50% reduction in migraine days or reduction in migraine days), and PREMIUM II (terminated early; modified ITT n=113) also failed to meet its primary outcome; a greater percentage of patients achieving a ≥50% reduction was seen in one analysis, but overall certainty was judged low to very low. Collectively, the RCTs and systematic review do not provide sufficient evidence to conclude nVNS improves net health outcomes for prevention of chronic migraine.

Coding — Procedure and Diagnosis Codes

CPT CodesCPT

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrodes; cranial nerve.
64568	Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter; with simple cranial nerve neurostimulator pulse generator/transmitter programming.
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter; with complex cranial nerve neurostimulator pulse generator/transmitter programming.

HCPCS Codes (investigational)HCPCSNot Covered

E0735

Non-invasive vagus nerve stimulator

ICD-10 Diagnosis Codes (examples listed)ICD-10

G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus.
G40.001	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus.
G40.009	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus.
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus.
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus.
R56.9	Unspecified convulsions.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required — Inpatient

Inpatient procedures described in this policy require precertification/preauthorization when performed in an inpatient setting.

Precertification/preauthorization IS REQUIRED if the procedure is performed inpatient.

Prior Authorization

Prior Authorization and Investigational Indications

Outpatient prior authorization is not routinely required for the services listed; however, payer-specific rules may apply for certain commercial product lines and situations. Check member contract and payer procedures for outpatient prior authorization requirements.

Commercial Managed Care (HMO and POS), Outpatient = Prior authorization is not required.
Commercial PPO and Indemnity, Outpatient = Prior authorization is not required.
When outpatient prior authorization might be required, follow payer procedures and any product-specific rules.

Background and Scope

Vagus nerve stimulation delivers pulsed electrical stimulation to vagal afferent and efferent fibers, producing widespread central nervous system effects via projections from the nucleus of the solitary tract to multiple brain regions. Implantable VNS was originally developed for medically refractory partial‑onset seizures and has been investigated for generalized seizures and a range of other neurologic and psychiatric conditions. The precise therapeutic mechanisms remain incompletely understood, and different approaches (implantable cervical systems versus transcutaneous/noninvasive devices) have distinct evidence bases and coverage considerations.

Definitions

inv-26: Vagus nerve stimulation (VNS) — implanted and transcutaneous approaches

DefinitionVagus nerve stimulation (VNS) — application of pulsed electrical stimulation to axons of the vagus nerve delivered via an implanted pulse generator and electrode(s); implanted systems are placed in proximity to the cervical vagus nerve (within the carotid sheath or adjacent structures) and have been used for refractory seizures and investigated for other disorders.

Implant location noteImplanted stimulators may be placed within the carotid artery sheath or at other areas of the vagus nerve trunk; other types placed at the gastroesophageal junction are not addressed in this review.

Mechanism summaryElectrical stimulation of vagal afferent and efferent fibers produces widespread central nervous system effects via brainstem projections (nucleus of the solitary tract) and can influence autonomic targets such as heart and gastrointestinal innervation.

Clinical use contextImplanted VNS is an established therapy for medically refractory partial‑onset seizures and has been studied for generalized seizures, depression, cardiac and other indications.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyVagus Nerve Stimulation (VNS) — Coverage Criteria

Policy CodePolicy 474

Change TypeClarified investigational indicationsliterature update

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required when the VNS procedure is performed inpatient.

SourceLink

On This Page

Rheumatoid arthritis (implantable VNS): Pilot sham-controlled RCTs and a multicenter sham-controlled pivotal trial (RESET-RA) show feasibility and some prespecified responder endpoint superiority in manufacturer documents, but peer-reviewed outcome data are limited and secondary outcomes inconsistent; evidence insufficient.

Published peer-reviewed data are limited; additional large trials needed.

Other neurologic/psychiatric/metabolic disorders with tVNS or implantable VNS: Conditions such as essential tremor, headache subtypes, fibromyalgia, tinnitus, autism, schizophrenia, impaired glucose tolerance, and stroke (for tVNS) have small RCTs or case series with methodological limitations and no definitive efficacy; evidence insufficient.

Case series are insufficient to draw conclusions regarding efficacy.

Cluster headache (tVNS) — preventive and acute: RCTs and systematic reviews show reductions in attack frequency in some trials but overall low certainty; acute treatment RCTs (ACT1/ACT2) show benefit in episodic subgroups but mixed results overall; evidence insufficient for net health benefit.

Episodic vs chronic responses differ; quality of evidence low to very low.

Migraine (acute and preventive) with tVNS: Acute migraine RCTs showed some secondary benefit measures but not primary endpoints; preventive trials (PREMIUM, PREMIUM II, EVENT) failed to show consistent superiority to sham and evidence judged low to very low; insufficient to determine net health benefit.

Phase 3 trials did not consistently demonstrate superiority to sham.

Note

Prior Authorization Influenced by CMS / NICE Guidance

Coverage determinations and prior authorization requirements may be influenced by external guidance from CMS and NICE (including NCDs, CED documents, and NICE interventional or technology guidance). Providers should be aware that these external policies can affect authorization decisions and documentation expectations.

Refer to CMS National Coverage Determination (Vagus Nerve Stimulation NCD 160.18) and CMS Coverage with Evidence Development materials.
Refer to relevant NICE guidance (IPG552, MIB162, MTG46, IPG679) for additional context that may inform coverage reviews.

Denial Risk

Investigational Indications — Potential Denial

Vagus nerve stimulation and transcutaneous VNS are considered investigational for multiple indications beyond established uses; requests for these investigational indications may be denied. Ensure documentation clearly supports the requested indication and aligns with policy-covered uses.

Investigational / potential denial-risk indications include, but are not limited to: heart failure, upper-limb impairment due to stroke, essential tremor, headaches (except as covered per policy), rheumatoid arthritis, fibromyalgia, tinnitus, traumatic brain injury.
Clinical evidence summarized in the policy indicates insufficient evidence for many of these uses; authorization for investigational indications is not supported by current evidence.

Billing Rule

Billing and Coding — Provider Reporting Requirement

Providers must report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including applicable modifiers. Inclusion of codes in the policy is informational and does not guarantee coverage — verify member contract benefits and code-specific requirements.

Use current CPT/HCPCS/ICD-10 and modifier codes when billing.
Inclusion or exclusion of a code in the policy does not imply coverage or reimbursement; confirm benefits at time of service.

Documentation Required

Documentation Requirements and Clinical Evidence

Documentation submitted with prior authorization requests should support the specific indication and reference pertinent clinical evidence when available. For devices and procedures with randomized controlled trial evidence (e.g., VNS for epilepsy) include trial history, prior therapies tried, and outcome measures; for investigational uses, note that stronger evidence is generally required and may not be available.

Document trials of medical therapy (e.g., for epilepsy or depression) and treatment refractoriness where applicable.
Include relevant clinical notes, prior authorizations, outcome measures, and citations to RCTs or guideline statements when available.

Step Therapy

Step Therapy — None Specified

No formal step therapy requirements are specified in the references for these services in this policy. Clinical context from guidelines and trials should guide treatment sequencing (for example, VNS is typically considered for seizures refractory to appropriate medication trials).

Step therapy: none specified in policy references.
Clinical practice: VNS considered after failure of appropriate medication trials for refractory epilepsy; for depression follow guideline-defined treatment‑resistant criteria.

Note

Required Supporting Guidance Documents

Keep available the required supporting guidance documents and external resources used to support authorization decisions. These should be accessible to clinical reviewers during prior authorization and appeals.

NICE guidance documents (IPG552, MIB162, MTG46, IPG679)
CMS NCD and CED materials for VNS (NCD 160.18; Coverage with Evidence Development)
Relevant guideline and trial publications cited in the policy (AAN, APA, key RCTs and systematic reviews).

inv-27: tVNS / nVNS — definition of transcutaneous / noninvasive devices

DefinitiontVNS / nVNS — transcutaneous or noninvasive vagus nerve stimulation devices that deliver stimulation externally rather than via implanted systems; may target cervical branches or auricular branches of the vagus nerve.

Device deliveryStimulation is applied externally (transcutaneously) using handheld or wearable stimulators rather than an implanted pulse generator and lead system.

Indications and evidenceTranscutaneous devices have been investigated for cluster headache, migraine, epilepsy, stroke rehabilitation, and other conditions; current evidence is generally insufficient for many indications per this policy.

Coding statusTranscutaneous (nonimplantable) VNS devices are listed as investigational in this policy (HCPCS E0735).

inv-28: Vagus nerve stimulation (VNS) — implanted cervical VNS definition for neurologic/psychiatric/cardiac indications

Implanted cervical VNS — definitionImplanted cervical VNS refers to an implanted pulsed electrical stimulator and electrode(s) positioned to stimulate the cervical vagus nerve (often within the carotid sheath) with a subcutaneously implanted pulse generator connected to lead(s).

Primary neurologic indicationImplanted cervical VNS is an established treatment option for medically refractory partial‑onset seizures based on randomized and observational studies reporting reductions in seizure frequency.

Other investigated indicationsImplanted cervical VNS has been investigated for treatment‑resistant depression, chronic heart failure, stroke rehabilitation, rheumatoid arthritis and other disorders, but evidence is insufficient for many non‑epilepsy indications per this policy.

ExclusionsOther implantable stimulators placed at the gastroesophageal junction are excluded from this evidence review and are not considered herein.

inv-29: Non-invasive vagus nerve stimulation (nVNS / tVNS / ta-VNS) — external cervical or auricular stimulation devices definition

DefinitionNon‑invasive vagus nerve stimulation (nVNS / tVNS / ta‑VNS) — external devices that stimulate the vagus nerve transcutaneously at cervical or auricular sites for acute or preventive therapy without surgical implantation.

Target sitesDevices may deliver stimulation to the cervical branch transcutaneously (cervical tVNS) or to the auricular branch (ta‑VNS) via the ear; handheld stimulators are commonly used in trials for headache disorders.

Clinical investigationsnVNS/tVNS has been studied for prevention and acute treatment of cluster headache and migraine, and investigated in epilepsy, stroke rehabilitation, and other conditions; evidence quality varies and is often insufficient to establish net health benefit.

Guidance and assessmentSystematic reviews and RCTs (eg, PREVA, ACT1/ACT2, PRESTO) and health technology assessments have evaluated these devices; NICE and other guidance are cited in the evidence base.